NCT00889382 is a Phase 1, PHASE2 clinical trial of OSI-906 in Ovarian Cancer, sponsored by Astellas Pharma Inc.

Who is sponsoring NCT00889382?

NCT00889382 is sponsored by Astellas Pharma Inc.

What drugs are being tested in NCT00889382?

Interventions in NCT00889382: OSI-906, Paclitaxel.

What condition does NCT00889382 study?

NCT00889382 studies Ovarian Cancer, Solid Tumors.

Is NCT00889382 still recruiting?

NCT00889382 is currently completed. Last updated 20 November 2024.

Last reviewed 2024-11-20 · How we verify

NCT00889382

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)

Completed Phase 1, PHASE2 Last updated 20 November 2024

What this trial tests

Phase 1, PHASE2 trial testing OSI-906 in Ovarian Cancer in 152 participants. Completed in 25 August 2014.

Timeline

5 August 2009

Primary endpoint
1 August 2014

25 August 2014

Quick facts

Lead sponsor	Astellas Pharma Inc
Phase	Phase 1, PHASE2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	152
Start date	5 August 2009
Primary completion	1 August 2014
Estimated completion	25 August 2014
Sites	46 locations across Italy, Russia, United Kingdom, Poland, Romania, Canada, Switzerland, Australia

Drugs / interventions tested

OSI-906 — full drug profile →
Paclitaxel — full drug profile →

Conditions studied

Ovarian Cancer — all drugs for Ovarian Cancer →
Solid Tumors — all drugs for Solid Tumors →

Sponsor

Astellas Pharma Inc — full company profile →

Who can join

18 and older, any sex, with Ovarian Cancer or Solid Tumors. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a multi-center, randomized, open-label, phase 1/2 study of continuous weekly paclitaxel and escalating doses of intermittent or continuous OSI-906 in patients with recurrent/relapsed ovarian and other solid tumors.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Molecular Pathways: Clinical Applications and Future Direction of Insulin-like Growth Factor-1 Receptor Pathway Blockade.
Iams WT, Lovly CM. · · 2015 · cited 144× · PMID 26429980 · DOI 10.1158/1078-0432.ccr-14-2518
New perspectives on targeted therapy in ovarian cancer.
Coward JI, Middleton K, Murphy F. · · 2015 · cited 77× · PMID 25678824 · DOI 10.2147/ijwh.s52379
The insulin-like growth factor 1 pathway is a potential therapeutic target for low-grade serous ovarian carcinoma.
King ER, Zu Z, Tsang YT, Deavers MT, et al · · 2011 · cited 44× · PMID 21726895 · DOI 10.1016/j.ygyno.2011.06.016
Phase 2 study evaluating intermittent and continuous linsitinib and weekly paclitaxel in patients with recurrent platinum resistant ovarian epithelial cancer.
Oza A, Kaye S, Van Tornout J, Sessa C, et al · · 2018 · cited 31× · PMID 29454514 · DOI 10.1016/j.ygyno.2018.01.019
The insulin and igf-I pathway in endocrine glands carcinogenesis.
Malaguarnera R, Morcavallo A, Belfiore A. · · 2012 · cited 20× · PMID 22927847 · DOI 10.1155/2012/635614
Modulation of insulin-like growth factor-1 receptor and its signaling network for the treatment of cancer: current status and future perspectives.
Jin M, Buck E, Mulvihill MJ. · · 2013 · cited 15× · PMID 25992224 · DOI 10.4081/oncol.2013.e3
Dietary or pharmacological inhibition of insulin-like growth factor-1 protects from renal ischemia-reperfusion injury in mice.
Lyon A, Agius T, Macarthur MR, Kiesworo K, et al · · 2024 · cited 2× · PMID 39759002 · DOI 10.1016/j.isci.2024.111256
The surgical, histopathological characteristics, and survival outcome of ovarian clear cell carcinoma: a retrospective case series sharing the experience of a tertiary cancer centre.
El Tawab S, Nistor S, Roux R, Manek S, et al · · 2024 · cited 2× · PMID 39430857 · DOI 10.21037/tcr-24-83

Verify or expand the search:

Other trials of OSI-906

Trials testing the same drug.

NCT01529684 — A Study to Look at How a Single Oral Dose of 14C-OSI-906 is Absorbed, Broken Down and Eliminated in the Body · Phase 1 · completed
NCT01221077 — Study of Erlotinib (Tarceva®) in Combination With OSI-906 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) W · Phase 2 · completed
NCT01186861 — Phase 2 Study of Maintenance OSI-906 Plus Erlotinib (Tarceva®), or Placebo Plus Erlotinib in Patients With Nonprogressio · Phase 2 · completed
NCT01101906 — A Randomized, Placebo-controlled, Double-blind Phase 2 Study With OSI-906 in Patients With Advanced HCC · Phase 2 · terminated
NCT00924989 — A Study of OSI-906 in Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma · Phase 3 · completed

Other recruiting trials for Ovarian Cancer

Currently open trials in the same condition.

NCT06412120 — Study Evaluating Safety, Tolerability, and Metabolism of Niraparib · Phase 4 · recruiting
NCT06930755 — Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer · Phase 1 · recruiting
NCT07318558 — A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021) · Phase 3 · recruiting
NCT07491081 — EARLY Study: Evaluating the Specificity and Feasibility of the EARLY Biomarker Panel for Ovarian Cancer Detection · NA · recruiting
NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting

Other Astellas Pharma Inc trials

Trials by the same sponsor.

NCT07318714 — A Study of ASP2246 for People Who Have Movement Problems Caused by Brain Injury After a Stroke · Phase 1, PHASE2 · recruiting
NCT07094204 — A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors · Phase 1 · recruiting
NCT06970665 — A Study About the Safety of ASP3021 Eye Injections and if They Help People in Japan With Vision Loss From Age-related Ma · Phase 4 · recruiting
NCT06364696 — A Study to Find a Suitable Dose of ASP4396 in Adults With Solid Tumors · Phase 1 · active not recruiting
NCT06206421 — A Study to Assess Long-term Safety of Fezolinetant Given to Japanese Women Going Through Menopause · Phase 3 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00889382 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Astellas Pharma Inc
Last refreshed: 20 November 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00889382.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing